Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.
Johannes Wiegand,Peter Buggisch,Wulf O. Boecher,Stefan Zeuzem,Cornelia M. Gelbmann,Thomas Berg,Wolfgang Kauffmann,Birgit Kallinowski,Markus Cornberg,Elmar Jaeckel,Heiner Wedemeyer,Michael P. Manns +11 more
Reads0
Chats0
TLDR
In acute HCV infection, early treatment with peginterferon α2b leads to high virological response rates in individuals who are adherent to treatment, and future studies should identify factors predicting spontaneous viral clearance to avoid unnecessary therapy.About:
This article is published in Hepatology.The article was published on 2006-02-01 and is currently open access. It has received 238 citations till now.read more
Citations
More filters
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection European Association for the Study of the Liver ⇑
TL;DR: The EASL CPGs on the management of HCV infection will be updated on a regular basis upon approval of additional novel therapies, and will apply to therapies that are approved at the time of their publication.
Journal ArticleDOI
Treating viral hepatitis C: efficacy, side effects, and complications
TL;DR: The efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations are described.
Journal ArticleDOI
Peginterferon and Ribavirin for Chronic Hepatitis C
TL;DR: A 44-year-old woman with chronic hepatitis C has intermittent fatigue and persistent elevations in serum alanine aminotransferase levels, and treatment with peginterferon and ribavirin is recommended.
Journal ArticleDOI
Lancet Seminar – Hepatitis C
TL;DR: Advances in HCV cell culture have enabled improved understanding of HCV virology, which has led to development of many new direct-acting antiviral drugs that target key components of virus replication, allowing for simplified and shortened treatments for HCV that can be given as oral regimens with increased tolerability and efficacy.
Journal ArticleDOI
Hepatitis C virus infection
Michael P. Manns,Maria Buti,Edward Gane,Jean-Michel Pawlotsky,Jean-Michel Pawlotsky,Homie Razavi,Norah A. Terrault,Zobair M. Younossi +7 more
TL;DR: The HCV pandemic has to be controlled by treatment-as-prevention strategies, effective screening programmes and global access to treatment, including populations that have been difficult to treat in the past.
References
More filters
Journal ArticleDOI
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Michael W. Fried,Mitchell L. Shiffman,K. Rajender Reddy,C. Smith,George Marinos,Fernando L. Gonçales,Dieter Häussinger,Moisés Diago,Giampiero Carosi,Daniel Dhumeaux,Antonio Craxì,A. Lin,Joseph Hoffman,Jian Yu +13 more
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Journal ArticleDOI
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Michael P. Manns,John G. McHutchison,Stuart C. Gordon,Vinod K. Rustgi,Mitchell L. Shiffman,Robert Reindollar,Zachary Goodman,Kenneth Koury,Mei Hsiu Ling,Janice K. Albrecht +9 more
TL;DR: In patients with chronic hepatitis C, the most effective therapy is the combination of peginterferon alfa-2b 1.5 microg/kg per week plus ribavirin, and this randomised trial found that the benefit is mostly achieved in patients with HCV genotype 1 infections.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
The natural history of community-acquired hepatitis C in the United States.
Miriam J. Alter,Harold S. Margolis,Krzysztof Krawczynski,Franklyn N. Judson,A Mares,W J Alexander,P Y Hu,J K Miller,Michael A. Gerber,R E Sampliner +9 more
TL;DR: Patients with community-acquired hepatitis C have a high rate of chronic hepatitis, and in most patients HCV infection seems to persist for at least several years, even in the absence of active liver disease.
Journal ArticleDOI
Natural history of chronic hepatitis C
TL;DR: Efforts to determine natural history are handicapped by the primary characteristics of the disease, namely that its onset rarely is recognized and its course is prolonged exceedingly, so that at least 20% of chronically infected adults develop cirrhosis within 20 years.